sumitomo pharma press release
「sumitomo pharma press release」熱門搜尋資訊
「sumitomo pharma press release」文章包含有：「PressReleases」、「NewsRoom」、「ForthePress」、「SumitomoPharmaAmericaNewsroom」、「【Jointpressrelease】SumitomoPharmaandPoxel...」、「SumitomoPharmaAnnouncesFDAAcceptanceof...」、「IRNews」、「StayUptoDatewithOurNews&Releases」、「SumitomoPharmalaysoff400USstaffersassalesslide」、「OtsukaandSumitomoReviseLicenseAgreement」
查看更多
Press Releases
https://www.sumitomo-pharma.co
Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological ...
News Room
https://www.sumitomo-pharma.co
Information concerning pharmaceuticals and medical devices (including those that are under development) within this News Room are made available solely for ...
For the Press
https://www.sumitomo-pharma.co
Aug. 07, 2024 【Joint press release】Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of ...
Sumitomo Pharma America Newsroom
https://news.us.sumitomo-pharm
Jul 15, 2024. Sumitomo Pharma Announces that DSP-5336 Has Received FDA Fast Track Designation for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia.
【Joint press release】Sumitomo Pharma and Poxel ...
https://www.sumitomo-pharma.co
In October 2017, Sumitomo Pharma concluded a development and commercialization partnership agreement for Japan, Chinese mainland, Taiwan, Korea ...
Sumitomo Pharma Announces FDA Acceptance of ...
https://www.prnewswire.com
Sumitomo Pharma Announces that DSP-5336 Has Received FDA Fast Track Designation for the Treatment of Relapsed or Refractory Acute Myeloid ...
IR News
https://www.sumitomo-pharma.co
Information concerning pharmaceuticals and medical devices (including those that are under development) within this News Room are made available solely for ...
Stay Up to Date with Our News & Releases
https://www.us.sumitomo-pharma
Jul. 31, 2023. Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia.
Sumitomo Pharma lays off 400 US staffers as sales slide
https://www.fiercepharma.com
The Japanese drugmaker is letting go of 400 staffers this month. The job cuts at Sumitomo Pharma America come amid a “severe business environment.”
Otsuka and Sumitomo Revise License Agreement
https://otsuka-us.com
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces the revision of the license agreement signed in September 2021 with Sumitomo Pharma Co., Ltd.